Wai Yuen Tong Medicine Holdings Limited is an investment holding company engaged in the production and sale of Chinese and Western pharmaceuticals and health food products primarily in Hong Kong, Mainland China and Macau. The company manufactures, processes and sells traditional Chinese medicines under the Wai Yuen Tong brand, including flagship over-the-counter products such as Hou Tsao Powder (猴棗除痰散), Angong Niuhuang Wan (安宮牛黃丸), Young Yum Pills (養陰丸), White Phoenix Pills (白鳳丸), Wild Cordyceps Plus (野生蟲草皇), Nano Bone Enhancer (骨盈素), Premium Ganoderma Eight Plus (百草靈芝皇), Body Dampness Relief (祛濕清) and Ultimate Brightening (雪肌丸); provides Traditional Chinese Medicine (TCM) consultation services and management and promotion services; and produces Western pharmaceutical and personal care products under the Madame Pearl’s brand, notably cough syrup which holds the number one market position in Hong Kong for 15 consecutive years, and the Pearl’s brand. It also invests in commercial and retail properties for rental income. Founded in 1897 and headquartered in Kowloon Bay, Hong Kong, the company operates through a network of retail stores under self-operating and franchise models, integrated TCM healthcare centres, and e-commerce channels including cross-border platforms like Douyin; it is a subsidiary of Rich Time Strategy Limited with 759 employees as of March 2025. Recent developments include the October 2025 approval of Hou Tsao Powder as Hong Kong's first traditional oral proprietary Chinese medicine for Mainland China listing under the Greater Bay Area simplified OTC registration scheme, enabling market entry in 2026; substantial 154% growth in cross-border e-commerce sales for the six months ended September 2025 driven by enhanced marketing and distribution; launch of new products like Body Dampness Relief which became a top-selling health supplement; introduction of AI TCM diagnostic systems and CRM upgrades at premier stores; expansion of Madame Pearl’s distribution to over 40,000 outlets in Mainland China including hospitals and e-pharmacies; property disposals yielding HK$153.4 million in considerations during fiscal 2025 including Shops in Tsuen Wan, Nathan Road, Kwun Tong, Aberdeen and Yen Chow Street; and no dividend recommendation for fiscal 2025 amid a shift to profit of HK$7.1 million attributable to owners after prior-year loss.